- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04805112
Acceptability, Feasibility and Impact of Oral HIV Self-testing for Partner Testing Among Kenyan Adolescent Girls Aged 15-19 Years: A Randomized Controlled Trial
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study will recruit HIV-negative adolescents girls (AG) aged 15-19 years in Siaya County, western Kenya. The study will evaluate the impact of the provision of oral HIV self-testing on uptake of testing among partners of adolescent girls. We will randomize about 300 sexually active AG to either an intervention group that receives multiple oral self-test kits that they can choose to offer to their sexual partner(s) or to a control group that will be given multiple referral coupons that their partners can use for HIV testing at pre-selected HIV testing services (HTS) sites. We will collect data on whether the kits were offered, to whom they were offered, if they were accepted, if they were used and with what results, if known, and if the partners who obtained HIV-positive results sought confirmatory testing. We will also conduct in-depth interviews with a sub-set adolescents to explore their experiences in offering HIV self-testing to their male partners.
This study has 4 specific aims: i) determine whether adolescent girls can safely offer oral HIV self-tests to their partners; ii) assess whether oral self-testing improves uptake of HIV testing among partners of adolescent girls; iii) document adverse events associated with offering oral self-testing to sexual partners of adolescent girls; and iv) qualitatively explore the experiences of adolescent girls when offering self-test kits to their partners.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Kisumu, Kenia
- Impact Research & Development Organization
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Female
- Aged 15-19 years
- HIV-negative (willing to self-test onsite in the presence of the Research Assistant who is also a trained HIV counselor)
- Has at least one current sexual partner she expects to meet at least twice in the next 3 months (not necessarily to have sex); this will provide opportunity for the participant to suggest/offer testing.
- Resides in Siaya County and does not intend to relocate within 6 months from enrollment, to allow follow up to be completed and to conduct IDI with those selected.
- Willing to be randomized into the partner self-testing or HTS referral groups.
- Reporting no incident of sexual, physical, emotional, or economic abuse in the last 12 months from the partner she intends to offer (Appendix 4) or refer for testing (Appendix 3) in the next 3 months and does not believe the partner will abuse her if she offers the self-test kits or HTS referral coupon.
- Has a male partner who has not tested for 6 months or whose HIV status is unknown to her.
- Agrees to give consent to participate in the study.
Exclusion Criteria:
- Male
- HIV-positive
- Not willing to self-test onsite under in the presence of the Research Assistant
- Aged <15 years or >19 years
- Does not have a current sexual partner or does not expect to meet the partner at least twice in the next 3 months
- Does not reside in Siaya County or intends to relocate within the next 6 months
- Not interested in obtaining HIV self-tests or HTS referral coupon for purposes of suggesting testing to their sexual partners
- Reporting an incidence of sexual, physical, emotional or economic abuse in the last 12 months from the partner she would have offered self-test kit or referred for testing, or believes the partner may subject her to sexual, physical, emotional, or economic abuse if she offered them self-test kit or HTS coupon.
- Has a male partner who tested within the last 6 months.
- Does not give consent to participate in the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Provision of multiple self-tests
Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s).
The participant will be instructed to encourage their partner to test himself alone [partner testing] or with the participant [couple testing]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing.
All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
|
Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing.
Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
|
Geen tussenkomst: Referral vouchers for clinic testing
Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites.
The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone [partner testing] or together with the participant [couple testing].
The coupon will also have information on testing and a list of facilities where he can go for HTS.
All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
uptake of partner HIV testing
Tijdsspanne: 3 months
|
proportion of partners that complete HIV testing
|
3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Introduce testing
Tijdsspanne: 3 months
|
proportion of participants who introduce testing to their partners
|
3 months
|
Partner accept testing
Tijdsspanne: 3 months
|
proportion of partners who were offered HIVST or referral coupon and accepted
|
3 months
|
Partner testing
Tijdsspanne: 3 months
|
proportion of participants who report their partner tested alone
|
3 months
|
Couples testing
Tijdsspanne: 3 months
|
proportion of participants who report testing with their partner
|
3 months
|
Positive partner
Tijdsspanne: 3 months
|
proportion of participants who report their partner test result was positive
|
3 months
|
linked to care
Tijdsspanne: 3 months
|
Proportion of participants who report their partners was linked to care
|
3 months
|
Intimate partner violence
Tijdsspanne: 3 months
|
proportion of participants in each study group who report intimate partner violence related to HIV testing
|
3 months
|
Confirmatory testing for positive HIV self-test
Tijdsspanne: 3 months
|
proportion of participants in the intervention group who report their partner tested positive and went for confirmatory testing
|
3 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Kawango Agot, PhD, Impact Organization & Research Development
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- Langzame virusziekten
- HIV-infecties
- Verworven Immunodeficiëntie Syndroom
Andere studie-ID-nummers
- 848410
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Humaan Immunodeficiëntie Virus
-
Fundación Pública Andaluza Progreso y SaludGilead SciencesVoltooidHuman Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Co-geïnfecteerde proefpersonenSpanje
-
National Taiwan University HospitalWervingHepatitis C-virusinfectie | Hepatitis C-virusinfectie, reactie op therapie van | Human Immunodeficiency Virus (HIV) co-infectieTaiwan
-
University of CincinnatiWervingPapillomavirus vaccins | Human Papillomavirus-virussenVerenigde Staten
-
Centre Hospitalier de CayenneVoltooidHuman Papillomavirus-virussen
-
Nutricia ResearchActief, niet wervendGroei | Tolerantie | Veiligheid | Onderwerpen die behoefte hebben aan een Human Milk Fortifier (HMF)Nederland, Frankrijk, Duitsland, Verenigd Koninkrijk
-
Hoffmann-La RocheBeëindigdOestrogeenreceptor-positief (ER+)/Human Epidermal Growth Factor Receptor (HER2)-negatief Lokaal gevorderde of gemetastaseerde borstkankerCanada, Verenigde Staten, Verenigd Koninkrijk, Australië, Duitsland
-
U.S. Army Medical Research and Development CommandVoltooid
-
ModernaTX, Inc.Actief, niet wervend
-
ModernaTX, Inc.WervingRespiratoir sincytieel virusCanada, Verenigde Staten, Verenigd Koninkrijk, Puerto Rico
-
ModernaTX, Inc.Actief, niet wervendRespiratoir sincytieel virusVerenigde Staten, Panama
Klinische onderzoeken op Provision of multiple self-tests
-
BioTeke USA, LLCCSSi Life SciencesVoltooidCOVID-19Verenigde Staten
-
Jaeb Center for Health ResearchWervingTaaislijmziekteVerenigde Staten